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Abstract
Background: Plasma lipid profiling has emerged as a useful tool for understanding the pathophysiology of hepatic
injury and disease. Hepatic fibrosis results from chronic, progressive damage to the liver and can lead, in turn, to
more serious conditions such as hepatic cirrhosis and hepatocellular carcinoma. Thus, the present study aimed to
investigate the plasma lipid profiles of two types of hepatic fibrosis in order to aid the understanding of the
pathophysiology of hepatic fibrosis.
Methods: A liquid chromatography and mass spectrometry platform was used to reveal and compare the plasma
lipid profiles of two types of chemical-induced hepatic fibrosis. Rat models of centrilobular fibrosis and bile duct
fibrosis were established via chronic exposure to the known fibrogenic hepatotoxins, carbon tetrachloride (CCl4) or
lomustine (LS), respectively, over a 28-day period. To delineate the specific alterations in the lipid profiles as a result
of the hepatic fibrosis, we also employed non-fibrogenic hepatotoxicants (2-acetamidofluorene, N-nitrosodiethylamine,
and ethambutol) as well as 3-day treatment of CCl4 and LS, which did not induce fibrosis.
Results: Our assay platform identified 228 lipids in the rat plasma, and the global lipid profile clearly distinguished
these models from the control via principal component analysis. In addition, the alteration of the plasma lipid profile
caused by CCl4 and LS were clearly different. Furthermore, a number of lipids were identified as specific alterations
caused by fibrosis induced only by CCl4 and LS, respectively. Three lysophosphatidylcholines (LPC[18:3], LPC[20:4], and
LPC[22:6]), and three phosphatidylcholines (PC[18:2/20:4], PC[40:8], and PC[20:4/22:6]) are specific circulating lipids, the
levels of which were altered by both CCl4 and LS treatment; however, their levels were decreased by chronic exposure
to CCl4 and increased by chronic exposure to LS.
Conclusions: These results suggest that different types of chemical-induced hepatic fibrosis demonstrate clear
differences in their plasma lipid profiles. Our study provides insights into the alteration of plasma lipidomic profiles as a
result of the fibrosis of different parts of the hepatic lobule, and may help to understand the pathophysiology of
different types of hepatic fibrosis.
Keywords: Hepatic fibrosis, LC/MS, lipidomics, Plasma lipid profiling, Hepatotoxicity
Background
Lipids, such as phosphoglycerolipids, sphingolipids, and
neutral lipids, are components not only of cellular mem-
branes, but also of blood-circulating lipoproteins. In
addition, these lipids play important roles in multiple
biological processes, including apoptosis, inflammation,
proliferation, and differentiation [1–4]. Aberrations of
the tightly regulated lipid homeostasis mechanisms are
associated with hepatic injury and disease. Thus, the
characterization of the alteration of lipids associated
with such diseases and injuries would help in under-
standing their pathophysiology. It is well known that the
synthesis of lipoproteins is one of the key functions of
the liver. In addition, a recent study demonstrated that
the composition of the plasma lipids is closely correlated
with the lipids in the liver [5]. Therefore, plasma lipid
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profiling could be a useful tool for understanding hep-
atic pathophysiology. In fact, plasma lipid profiling has
already been applied to understanding the pathophysi-
ology, and to identifying biomarkers for hepatocellular
carcinoma [6, 7], liver phospholipidosis [8], and non-
alcoholic fatty liver disease [9].
Hepatic fibrosis can be defined as the accumulation
of extracellular matrix proteins that form excessive
connective tissue in the liver in the setting of etiologic-
ally diverse hepatic conditions such as alcoholic and
nonalcoholic liver disease, viral hepatitis, and disease
due to chemicals. In time, this may progress to more
serious conditions, such as cirrhosis and hepatocellular
carcinoma [10–12]. Thus, understanding the patho-
physiology of hepatic fibrosis is important and plasma
lipid profiling could be a useful tool for achieving this.
In addition, fibrosis may occur in different sections of
the classical hepatic lobule, depending on the agent
causing the insult. For instance, alcohol-induced fibro-
sis primarily affects the centrilobular regions [13],
whilst infection with the hepatitis C virus primarily
affects the portal area [14]. Chronic exposure to the
hepatotoxin carbon tetrachloride (CCl4) consistently
causes fibrosis in the centrilobular regions [15], whilst
that induced by lomustine (LS) causes fibrosis in the
bile ducts [16]. In the previous literature, the two main
functions of lipid homeostasis are also localized in
specific areas of the hepatic lobules. Catabolism (fatty
acid oxidation and phospholipid degradation) occurs
mainly in the periportal area, while anabolism (fatty
acid synthesis and fatty acid incorporation into phos-
pholipids and cholesterol esters [ChEs]) is more pre-
dominant in the centrilobular area [17, 18]. Thus, the
lipid alterations caused by hepatic fibrosis could vary
between different regions within the lobule where the
insult occurs.
In the present study, we used a rat model to investi-
gate the plasma lipid profiles of two types of hepatic fi-
brosis. Centrilobular fibrosis and bile duct fibrosis were
chemically induced by CCl4 and LS, respectively. To
analyze the plasma lipid profiles, we employed a recently
developed lipidomics platform comprising liquid chro-
matography and mass spectrometry (LC/MS), which
simultaneously determined the levels of a broad
spectrum of lipids. In total, we determined and exam-
ined 228 lipids (97 phospholipids, 23 sphingolipids, and
108 neutral lipids). The principal component analysis
clearly demonstrated differences in the plasma lipid pro-
files of rats with hepatic fibrosis against those of control
rats. In addition, we addressed the specific differences in
the lipid alterations of CCl4- and LS-induced hepatic fi-
brosis. We then identified specific plasma lipid mole-




The rat plasma samples used in the present study were
obtained from the toxicogenomics projects TGP and
TGP2 (pathophysiological data were deposited in the
Open TG-GATEs database [http://toxico.nibiohn.go.jp/])
[19]. The drug treatments and major histological find-
ings are summarized in Table 1. In brief, 6-week-old
male Crl:CD (SD) rats (Charles River Japan, Kanagawa,
Japan) were subjected to continuous treatment with the
fibrogenic chemicals, CCl4 or LS, for either 3 or 28 days
(i.e. chronic exposure over 28 days is known to consist-
ently induce hepatic fibrosis). For comparison purposes,
either 2-acetamido-fluorene (AAF), N-nitrosodiethylamine
(DEN), or ethambutol (ETB) was administered for 28 days
as a non-fibrogenic hepatotoxic control. Each drug-
treatment group (n = 5) had its own corresponding nega-
tive control group that was treated with the vehicle only
(n = 5). At the end of the trial, venous blood and livers
were isolated from the rats. Whole blood was subjected to
isolate the plasma fraction. The livers were fixed, paraffin-
embedded, and subjected to histopathological analyses to
evaluate the extent of the hepatic fibrosis and hepatopathy.
The use of the animal specimens was approved by the Eth-
ics Review Committee for Animal Experimentation of the
National Institute of Biomedical Innovation, Health, and
Nutrition (Osaka, Japan) and the National Institute of
Health Sciences (Tokyo, Japan).
Lipid extraction
Plasma (20 μL) was mixed for 1 min with methanol
(180 μL) containing 2 μM phosphatidylethanolamine
(PE; 12:0/12:0; Avanti Polar Lipids, Alabaster, AL) as an
internal standard. After mixing, the homogenate was
centrifuged at 15,000 g for 4 min to precipitate the cellu-
lar debris. The supernatant was collected, filtered, and
stored at a temperature of − 80 °C until use.
Lipid measurements
Measurements of the lipid content were performed as
per the following protocol. The samples were random-
ized for the LC/MS measurement. Lipid extracts were
separated by the LC system using an InertSustain Bio
C18 column (2.1 × 150 mm, 1.9 μm; GL Sciences, Tokyo,
Japan) connected to an Ultimate 3000 HPLC system
(Thermo Fisher Scientific, Waltham, MA). A binary
solvent system was used, in which the mobile phase A
consisted of acetonitrile:methanol:H2O (9:9:2) with
10 mM ammonium formate, and 0.1 % formic acid, and
the mobile phase B consisted of isopropanol: acetonitrile
(9:1) with 10 mM ammonium formate and 0.1 % formic
acid. The flow rate was set at 200 μL/min and the col-
umn oven was held at 55 °C. Before gradient elution, the
column was equilibrated with 0 % mobile phase B.
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Compound name Abbreviation Dose
(mg · kg−1 · day−1)
Duration
(days)
Control Chemicals Administration Vehicle control Fibrosis Cellular
infiltration
Necrosis Proliferation Ground glass
appearance
Carbon tetrachloride CCL4 100 28 5 5 peroral corn oil Centrilobular,
5/5 (minimal)
Centrilobular - - -





Periportal Midlobular Bile duct,
Kupffer cell
-
2-Acetamidofluorene AAF 300 28 5 5 peroral 0.5 w/v%
methylcellulose
negative Periportal - Bile duct,
Oval cell
-
N-Nitrosodiethylamine DEN 30 28 5 5 peroral 0.5 w/v%
methylcellulose
negative - Centrilobular Bile duct -
Ethambutol ETB 1000 28 5 5 peroral 0.5 w/v%
methylcellulose
0.5 w/v%
negative - Single cell - Centrilobular
Carbon tetrachloride CCL4 100 3 5 5 peroral corn oil negative Centrilobular - - -
Lomustine LS 6 3 5 5 peroral 0.5 w/v%
methylcellulose
0.5 w/v%
















Samples (5 μL) were injected, and the gradient elution
was initiated at 0 % mobile phase B for 0.1 min. It was
then increased to 40 % mobile phase B from 0.1 to
5 min; and then further increased to 55 % mobile phase
B from 5 to 10 min. The gradient elution was then fi-
nally increased to 95 % mobile phase B from 10 to
15 min, before maintaining it at 95 % mobile phase B for
a further 10 min. The column was equilibrated with 0 %
mobile phase B for 15 min before the next sample was
injected. Subsequently, the lipid compositions were de-
termined and measured by the MS system using a Q
Exactive mass spectrometer (Thermo Fisher Scientific).
The spray voltage was set to 3.5 and − 2.5 kV in positive
and negative ion modes, respectively. The following con-
ditions were held constant for both the positive and
negative ion modes. MS detection was performed with
alternation between the high mass accuracy full scan
(full MS) and data-dependent MS2 scan (dd-MS2) in
both the positive and negative ion modes; dd-MS2 was
set to Top 5. The scan resolutions for full MS and dd-
MS2 were 35 000 and 17 500, respectively. The scan
range of the MS was set to m/z 300–1600. Representa-
tive chromatograms of the plasma obtained from the
rats treated with CCl4 and LS for 28 days are presented
in Additional file 1: Figure S1.
Data processing
For the lipid quantification, the raw full MS data ob-
tained by LC/MS were processed using the 2DICAL
software (Mitsui Knowledge Industry, Tokyo, Japan),
which allowed the alignment of the detected ion peaks
of each biomolecule obtained at a specific m/z with the
column retention time (RT). The main parameters of
the 2DICAL software were set as described previously,
with a few modifications [20]. The absolute intensity
threshold of the ion detection was set to 50 000 and 500
000 for the peak extraction in the negative and positive
ion modes, respectively. For the alignment, the RT, m/z,
and detection tolerances were set as 0.25, 0.1 Da, and
20 %, respectively. For samples with missing values for a
lipid, 50 000 (negative ion mode) or 500 000 (positive
ion mode) was applied. The intensities of each extracted
ion peak were normalized to those of the internal stand-
ard (PE [12:0/12:0]). Subsequently, the lipids in the ex-
tracted ion peaks were identified via the processing of
the raw full MS and dd-MS2 data using the Lipid Search
software (Mitsui Knowledge Industry, Tokyo, Japan) in
the product search mode. This allowed the attribution of
the lipids’ identities from a combination of an accurate
m/z of the precursor ions and dd-MS2 spectral patterns.
The precursor and product tolerance were set to 10 and
15 ppm, respectively. All identified lipids are listed in
Table 2 and Additional file 2: Table S1. If more than two
lipid species possessed the same chemical formula,
alphabetical letters were added after each lipid class to
distinguish them from each other. All the obtained data
were normalized to the average of each control (the ad-
justed average control value was set as 1). The normal-
ized data, fold changes, and associated p-values of all the
samples from the experimental groups, when compared
with the controls, are listed in Additional file 2: Table S2
and Additional file 2: Table S3. The molecules with the
same formula but different fatty acid compositions
assessed by their retention times were discriminated by
small alphabetical letters, a and b, at the end of their
names.
Principal component analysis (PCA) and statistical tests
For the PCA, the control and drug-treated data sets
obtained from the rat plasma were loaded into
SIMCA-P+ 12 (Umetrics, Umea, Sweden) and analyzed
using PCA-X. To compare the relative plasma levels of
the lipids, Welch’s t-test was used to assess the statistical
difference in plasma lipid levels between the control and
drug-treated rats. Differences with p-values <0.05 were
considered statistically significant.
Results
Histopathologic characteristics of the rat livers
Rats treated for 28 days with CCl4 exhibited hepatic fi-
brosis and cellular infiltration in the centrilobular area
(Table 1). In contrast, LS treatment for 28 days induced
hepatic fibrosis in the bile duct, cellular infiltration in
the periportal area, necrosis in the midlobular area, and
the proliferation of bile duct epithelial cells and Kupffer
cells. The histologic sections of the rat livers treated for
28 days with CCl4 and LS are available in the Open TG-
Table 2 Identified lipid classes and the numbers of individual
lipid molecules
Lipid type Lipid classes Number of
molecules
Phosphoglycerolipid Lysophosphatidylcholine (LPC) 15
Lysophosphatidylethanolamine (LPE) 6
Phosphatidylcholine (PC) 43
Ether-type PC (ePC) 6
Phosphatidylethanolamine (PE) 10
Ether-type PE (ePE) 8
Phosphatidylinositol (PI) 9
Sphingolipid Sphingomyelin (SM) 15
Ceramide (Cer) 7
Glycosylceramide (GCer) 1
Neutral lipid Diacylglycerol (DG) 6
Cholesterol ester (ChE) 8
Triacylglycerol (TG) 94
Total 228
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GATEs database (http://toxico.nibiohn.go.jp/) [19], and
the representative sections are shown in Additional file 1:
Figure S2. Rats that were treated with the non-fibrogenic
hepatotoxicants, AAF, DEN, and ETB, exhibited no evi-
dent hepatic fibrosis by the end of the 28-day treatment
protocol. AAF induced cellular infiltration in the peripor-
tal area, along with the proliferation of bile duct epithelial
cells and oval cells. DEN induced necrosis in the centri-
lobular area, and proliferation of the bile duct epithelial
cells. ETB induced single cell necrosis and a generalized
ground-glass hepatocyte appearance in the centrilobular
area. Following 3 days of exposure (constituting the pre-
fibrosis stage), neither CCl4 nor LS exhibited evidence of
fibrosis. At that time, CCl4 induced cellular infiltration in
the centrilobular area; however, rats treated with LS dem-
onstrated no evidence of hepatopathy.
Plasma lipid profiling of rats treated with CCl4 or LS
From the qualification of the extracted ion peaks, the
lipidomic analysis identified 228 lipids, including 97
phospholipids, 23 sphingolipids, and 108 neutral lipids,
in the rat plasma (Table 2 and Additional file 2: Table
S1). These 228 lipids were subjected to the following
analysis. We first compared the plasma lipid profiles of
the rats treated with either CCl4 (centrilobular fibrosis)
or LS (bile duct fibrosis) with that of the control group
in order to establish whether they would demonstrate
specific differences in their plasma lipid profiles in com-
parison with the normal animals. As shown in Fig. 1a,
the PCA of the control and CCl4-treated rats demon-
strated a clear separation between these two groups. The
comparison between the PCA of the LS-treated rats and
their respective control also demonstrated a clear separ-
ation (Fig. 1b). These results indicate that each of the
plasma lipid profiles of the two fibrogenic groups were
significantly altered compared to those of the controls.
We then compared and contrasted the alterations in
the plasma lipid profiles caused by CCl4 and LS. As
shown in Fig. 2, the alterations in the plasma lipid pro-
files compared with the control group were clearly dif-
ferent between the CCl4- and LS-treated groups, with
some exceptions. In the case of the rats treated with
CCl4, there were decreases in the circulating levels of
some lysophosphatidylcholines (LPCs), phosphatidylcho-
lines (PCs), diacylglycerols (DGs), and triacylglycerols
(TGs). Conversely, in the rats treated with LS, there
were increases in the circulating levels of some LPCs,
lysophosphatidylethanolamines (LPEs), PCs, ether-type
PCs, ether-type PEs, phosphatidylinositols (PIs), sphin-
gomyelins (SMs), ChEs, and highly-unsaturated TGs.
Only a few lipids, mainly TGs such as TG(52:4),
TG(54:6)a, and TG(56:1), were commonly decreased in
this group. Therefore, it is clearly demonstrated that
the lipid profiles of the plasma are altered in very
different ways by the specific hepatopathies caused by
CCl4 and LS.
Specific lipid alterations in rats with CCl4- and LS-induced
hepatic fibrosis
Having demonstrated that CCl4 and LS alter the lipid
profile in markedly different ways, we next explored
whether these alterations were caused specifically by
hepatic fibrosis in their respective regions (centrilobular
versus portal), as opposed to non-fibrotic hepatopathies
in the same regions.
To achieve this, we first compared the alterations in
the plasma lipid profiles of CCl4 and LS with those of
three non-fibrogenic hepatotoxic chemicals (AAF, DEN,
and ETB) following a 28-day treatment period. Aspects
of the plasma lipid profiles altered by any of these non-
fibrogenic hepatotoxins by more than 50 % when com-
pared with the control group, or the demonstration of a
statistically significant difference (p < 0.05) from the con-
trol group, were defined as changes that were unrelated






















R2X[1] = 0.561804 R2X[2] = 0.147198
control CCL4
control LS
Fig. 1 Principle component analysis model of plasma lipid profiles.
Plasma lipid profiling data obtained from rats treated with CCl4 (a)
and LS (b) for 28 days, and those of their controls
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decreased following CCl4 treatment, only 10 out of 104
were specifically altered by CCl4, suggesting that they
may be specific changes seen in centrilobular fibrosis. In
contrast, of all the lipid levels increased by LS, 37 out of
70 were specifically increased by LS, which suggests that
they may be specific changes seen only in bile duct or
periportal fibrosis. There was no common specific lipid
alterations among CCl4 and LS, further indicating that
the alterations in their plasma lipid profiles may be spe-
cific to the region of the liver unit that undergoes
fibrosis.
To further specify the lipid alterations resulting from
hepatic fibrosis, we next compared the specific lipid al-
terations elicited by CCl4 or LS with those at the pre-
fibrosis stage (3-day treatment), in which neither CCl4
nor LS had induced fibrosis. Alterations in the plasma
lipid levels at the pre-fibrosis stage of >50 % compared
with the control group, or displaying a statistically sig-
nificant change (p < 0.05), were defined as changes that
were unrelated to fibrosis. As shown in Fig. 4, of the ten
specific lipids altered by CCl4, seven were specific to fi-
brosis (28-day treatment), whilst three were unrelated to
fibrosis. These seven lipids included three LPCs, three
PCs, and one ceramide (Table 3). In contrast, all of the
37 specific lipids altered by LS treatment were specific
for fibrosis (Fig. 4). These included four LPCs, 14 PCs,
three ether-type PEs, two PIs, five SMs, and nine TGs
(Table 3). Of these lipids, three LPCs (LPC[18:3],
LPC[20:4], and LPC[22:6]), and three PCs (PC[18:2/20:4
(38:6a)], PC[40:8], and PC[20:4/22:6 (40:10)]) were listed
in both CCl4 and LS, although the responses to these
chemicals were different. As an example, the changes in
the listings of LPC(18:3) and PC(18:2/20:4) are shown in
Fig. 5.
Discussion
In the present study, we used plasma lipid profiling to
characterize the alterations in the levels of the circulat-
ing lipids associated with two different types of hepatic
fibrosis in rat models; centrilobular fibrosis that was
Fig. 2 Heat maps of plasma lipid profiles of rats treated with CCl4 or LS for 28 days. (p < 0.05) lipid molecules was generated using the mean fold
changes in the levels of molecules, calculated as ratios against each control. Vacant white cells indicate lipids that did not show significantly
different levels. CC; carbon tetrachloride, LS; lomustine. The molecules with the same empirical formula but different structure, as assessed by the
retention time, were denoted by the addition of lower-case alphabetical suffixes. Other abbreviations were described in Table 2
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induced by CCl4 and bile duct fibrosis that was induced
by LS. Firstly, both treatment with CCl4 and LS clearly
resulted in lipid alterations when compared with the
control. Secondly, the lipid alterations elicited by CCl4
and LS were clearly different. Thirdly, a comparison be-
tween the treatment with non-fibrogenic hepatotoxins
and the pre-fibrotic state of the animals treated with
fibrogenic hepatotoxins revealed specific alterations that
were induced by CCl4 and LS. Decreases in the circulat-
ing plasma levels of three LPCs (LPC[18:3], LPC[20:4],
and LPC[22:6]) and three PCs (PC[18:2/20:4], PC[40:8],
and PC[20:4/22:6]) were found to be specific responses
to fibrogenic CCl4 treatment, suggesting that these
plasma lipid decreases are associated with centrilobular
hepatic fibrosis. On the other hand, fibrogenic LS-
specific alterations, including increases in the levels of
phospholipids (LPCs, PCs, ether-type PEs, PIs, and SMs)
and TGs, suggest that bile-duct fibrosis is associated
with the alteration of the plasma levels of these lipid
classes.
So far, the mechanism underlying the different plasma
lipid profiles as a result of CCl4 and LS exposure is un-
clear. However, it has been reported that the levels of
specific PCs, such as PC(18:2/20:4) and PC(40:8), de-
creased during fibrosis progression in the livers of a
mouse model of non-alcoholic steatohepatitis [21].
Taken together with this report, centrilobular hepatic fi-
brosis could induce a decrease in specific PCs, such as
PC(18:2/20:4) and PC(40:8), in the liver and then, subse-
quently, in the circulating plasma. On the other hand, it
has been reported that phospholipids were secreted into
the bile with bile salts, cholesterol, and bile pigments
[22]. In addition, artificial bile duct failure as a result of
bile duct ligation leads to increased levels of serum
phospholipids [23]. Thus, the increased levels of plasma
phospholipids, such as PCs and SMs, as a result of the
LS treatment may be associated with the functional fail-
ure of the bile secretion of phospholipids via the hasten-
ing of bile duct fibrosis. Alternatively, it has been
reported that the periportal area of the liver plays a
dominant role in fatty-acid degradation [17]. Thus, the
increased levels of the plasma lipids as a result of LS
treatment may also reflect the loss of periportal liver
function for the purpose of lipid catabolism. Taken
CCL4 (0) LS (70)
FNs (102)






CCL4 (104) LS (38)
FNs (147)








Fig. 3 Venn diagrams of the number of lipid molecules that showed
significantly different levels between the control and chemical-treated
rats (CCl4, LS and non-fibrogenic chemicals for 28 days). Increased:
chemical-treated rats > control, decreased; chemical-treated
rats < control. CCl4, carbon tetrachloride; FC, fold change; FNs,
non-fibrogenic chemicals; LS, lomustine
Post-fibrosis (28 day)
(10)
Pre-fibrosis  (3 day)
(129)












Fig. 4 Venn diagrams of the number of CCl4- (a) or LS- (b) specific
lipid molecules that showed significantly different levels between
the control and chemical-treated rats (CCl4 and LS for pre-fibrosis
and post-fibrosis stages). CCl4; carbon tetrachloride, FC; fold change,
LS; lomustine
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together, as the zonal heterogeneity of lipid metabolism
in the liver has been reported [17, 18], the mechanism
underlying the different plasma lipid profiles caused by
CCl4 and LS exposure might be due to the zone specifi-
city of the area of hepatic fibrosis.
Chronic CCl4 exposure also decreased the plasma
levels of a broad spectrum of DGs and TGs; however,
these were similar to those caused by hepatopathy asso-
ciated with either chronic exposure to ETB, which did
not lead to fibrotic changes (Additional file 1: Figure S3),
or with acute CCl4 exposure, prior to the onset of the fi-
brotic changes (Additional file 1: Figure S4). Chronic
ETB exposure induced the ground-glass appearance of
the hepatocytes of the centrilobular region upon histo-
pathological examination, whilst both the acute and
chronic exposure to CCl4 induced cellular infiltration
into the same area, suggesting that these pathophysio-
logical changes in the centrilobular area by ETB and
CCl4 could decrease the levels of plasma DGs and TGs.
It has been well-documented that the centrilobular area
plays a dominant role in lipid synthesis, including fatty-
acid synthesis and esterification [17]. Thus, the deceased
levels of plasma DGs and TGs may reflect a loss of the
centrilobular liver function.
On the other hand, LS treatment also increased the
levels of ether-type PCs, and this increase was observed in
rats treated with AAF and DEN (Additional file 1: Figure
Table 3 Candidate lipid markers for hepatic fibrosis induced by
CCL4 and LS
Class Ion Fatty side chains CCL4 LS
LPC LPC(18:0) 18:0 − ↑
LPC LPC(18:3) 18:3 ↓ ↑
LPC LPC(20:4) 20:4 ↓ ↑
LPC LPC(22:6) 22:6 ↓ ↑
PC PC(34:0) 16:0/18:0 − ↑
PC PC(36:0) 18:0/18:0 − ↑
PC PC(36:4)b 16:0/20:4 − ↑
PC PC(38:4)b 18:0/20:4 − ↑
PC PC(38:5) 18:1/20:4 − ↑
PC PC(38:6)a 18:2/20:4 ↓ ↑
PC PC(38:6)b 16:0/22:6 − ↑
PC PC(40:4) 18:0/22:4 − ↑
PC PC(40:5) 20:1/20:4 − ↑
PC PC(40:6)b 18:0/22:6 − ↑
PC PC(40:7) 18:1/22:6 − ↑
PC PC(40:8) N.D. ↓ ↑
PC PC(42:7) N.D. − ↑
PC PC(42:10) 20:4/22:6 ↓ ↑
ePE PE(38:5e)a N.D. − ↑
ePE PE(38:5e)b N.D. − ↑
ePE PE(40:5e) N.D. − ↑
PI PI(36:4) 16:0/20:4 − ↑
PI PI(40:6) 18:0/22:6 − ↑
SM SM(34:1) N.D. − ↑
SM SM(34:2) N.D. − ↑
SM SM(40:2) N.D. − ↑
SM SM(42:2) N.D. − ↑
SM SM(42:4) N.D. − ↑
Cer Cer(42:1) N.D. ↓ −
TG TG(54:6)b 16:0/18:2/20:4 − ↑
TG TG(56:5) 16:0/18:1/22:4 − ↑
TG TG(56:6) 18:1/18:1/20:4 − ↑
TG TG(58:6) 18:1/18:1/22:4 − ↑
TG TG(58:7) N.D. − ↑
TG TG(60:8) N.D. − ↑
TG TG(60:9) 18:1/18:2/24:6, 18:1/20:3/22:5 − ↑
TG TG(60:10) N.D. − ↑
TG TG(62:11) N.D. − ↑
The underline lipid molecules are altered by both CCl4 and LS. CCl4 carbon
tetrachloride; LS lomustine; LPC lysophosphatidylcholine; PC phosphatidylcholine;
ePE ether-type PC, PI phosphatidylinositol; SM sphingomyelin; Cer ceramide;
























































CC LS AA DE ET CC LS
28 day 3 day
Fig. 5 Representative lipid molecules altered only in the fibrosis
state. Data are presented as the normalized levels to the control and
shown as the mean ± standard deviation. p < 0.05 in paired t-tests
comparing the control and chemical-treated rats. AA; 2-acetamidofluorene,
CC; carbon tetrachloride, DEN; N-nitrosodiethylamine, ETB; ethambutol,
LS; lomustine. Other abbreviations are described in Table 2
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S3), which led to the proliferation of bile-duct epithelial
cells. These observations suggest that the increased
plasma levels of ether-type PCs are associated with the
proliferation of the bile-duct epithelium. Although the role
of ether-type PCs in bile duct proliferation remains un-
clear, it has been reported that higher levels of ether-type
PCs were detected in migratory breast cancer cells [24].
Thus, this increased level of plasma ether-type PCs might
be associated with the migratory process of the bile duct
epithelial cells.
In non-alcoholic steatohepatitis, which is one of the
major causes of hepatic fibrosis, the levels of plasma
lipids such as TGs and cholesterol were elevated and
their levels were inversely associated with the resolution
of non-alcoholic steatohepatitis [25, 26]. In addition,
dietary cholesterol worsens non-alcoholic steatohepatitis
[27–29]. In the present study, although our platform did
not target cholesterol, the levels of TGs were decreased
following CCL4 treatment. Thus, the elevation in plasma
TGs is associated with hepatic steatosis rather than hep-
atic fibrosis. Conversely, decreased TG and cholesterol
levels are associated with liver dysfunction and the pro-
gression of liver disease, but not cardiovascular risk, in
patients with non-alcoholic, alcoholic, or virus-induced
cirrhosis [30–34]. Thus, decreased TG levels might be
common features of hepatic fibrosis/cirrhosis and, there-
fore, are relevant in our CCl4-treated hepatic fibrosis
model based on plasma lipid profiling. However, the de-
creased levels of many TGs were observed as a result of
the pre-fibrogenic CCl4 treatment and non-fibrogenic
ETB treatment. Therefore, the precise clinical relevance
of our CCl4 hepatic fibrosis model remains to be investi-
gated in future studies. On the other hand, hyperlipid-
emia is an almost universal feature in primary biliary
cirrhosis [31]. In the present study, the LS treatment in-
creased the levels of plasma phospholipids, which were
related to the artificial bile duct failure as a result of bile
duct ligation [23]. Thus, hyperlipidemia might be a com-
mon feature of bile duct fibrosis/cirrhosis and, therefore,
relevant in our LS-treated bile duct fibrosis model based
on plasma lipid profiling.
Several blood markers for hepatic fibrosis have been
proposed (i.e. megamitochondria [35], type IV collagen
[36], hyaluronic acid [37], dehydroepiandrosterone [38],
and Mac-2-binding protein [39]). In the present study,
no specific plasma lipid was shared in rats treated with
CCl4 and LS; the inference being that there is no plasma
lipid commonly found in both types of hepatic fibrosis
that is affected in the same way. Therefore, we could not
consider a plasma lipid as a candidate for a common
biomarker of hepatic fibrosis. However, whilst three
LPCs and three PCs, such as LPC(18:3) and PC(18:2/
20:4), were specifically altered by both CCl4 and LS
treatments, the responses to these were the opposite of
each other. Thus, these lipid molecules are potential
markers that can discriminate between different types of
hepatic fibrosis.
Conclusion
In conclusion, we characterized the plasma lipid profiles
of rats chronically exposed to two hepatic fibrogenic and
three non-fibrogenic hepatotoxins using a lipidomics ap-
proach. Chronic CCl4 and LS exposure are known to
cause centrilobular and bile duct fibrosis, respectively.
By comparing the exposure of rats to both agents with a
corresponding vehicle control, we revealed that both
treatments induced specific alterations in the plasma
lipid profiles. In addition, by comparing CCl4 and LS
with non-fibrogenic hepatotoxicants, as well as the pre-
fibrotic stages of CCl4 and LS hepatopathy, we demon-
strated specific plasma lipid alterations as a result of
chronic CCl4 and LS exposure that may be indicative of
fibrosis in specific regions of the liver lobules. Our study
provides an insight into the alteration of the plasma lipi-
domic profiles, which probably reflect chemical-induced
hepatic fibrosis. These findings may help to understand
the pathophysiology of different types of hepatic fibrosis.
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